Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials

JP Rindone, CK Mellen, M Goldenstein - Hospital Pharmacy, 2024 - journals.sagepub.com
Background: The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to
enalapril in patients with reduced ejection fraction (HFrEF). Since its publication, several …
相关文章

Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials.

JP Rindone, CK Mellen, M Goldenstein - Hospital Pharmacy, 2024 - search.ebscohost.com
Abstract Background: The PARADIGM HF trial showed sacubitril/valsartan (SV) to be
superior to enalapril in patients with reduced ejection fraction (HFrEF). Since its publication …

Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials

JP Rindone, CK Mellen… - Hospital …, 2024 - pubmed.ncbi.nlm.nih.gov
Background: The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to
enalapril in patients with reduced ejection fraction (HFrEF). Since its publication, several …

Is Sacubitril/Valsartan a Superior Agent in Heart Failure With Reduced Ejection Fraction? A Review of Randomized Comparative Trials.

JP Rindone, CK Mellen, M Goldenstein - Hospital Pharmacy, 2023 - europepmc.org
Background: The PARADIGM HF trial showed sacubitril/valsartan (SV) to be superior to
enalapril in patients with reduced ejection fraction (HFrEF). Since its publication, several …